Abstract：Objective To analyze the survival of patients with esophageal cancer.Methods Fifty-four patients with esophageal cancer were selected between May 2012 and January 2018 in Lishui People’s Hospital. Patients were reexamined every 3 to 6 months in the first year, followed by follow-ups every 6 to 12 months, and routine chest and abdominal CT was performed. Related information on surgery of esophageal cancer was retrieved from the department of medical records, electronic medical records were consulted from the HIS system to find out about the re-hospitalization of these patients, and the patients were followed up on the telephone asking about the therapeutic effect and survival. The follow-up deadline was January 31, 2018. The median duration of follow-up was 20 months. One case was later out of touch and the follow-up rate was 98.8%.Results The 1-year, 3-year and 5-year recurrence-free survival rates of these 54 patients were 66.1%, 58.1% and 58.1%, respectively. The overall survival rates were 83.4%, 61.8% and 61.8% respectively. The overall survival rate of esophageal cancer was related to age (OR 3.848, 95% CI 1.047-14.143)and lymph node metastasis(OR 4.777, 95% CI 1.165-19.594), but not to chemotherapy.Conclusions Total postoperative survival rate in patients with esophageal cancer is related to age and lymph node metastasis. Postoperative adjuvant chemotherapy fails to show any significant advantage.
Pennathur A, Gibson M K, Jobe B A,et al. Oesophageal carcinoma [J]. Lancet,2013,381 (9864): 400-412.
[2]
Shridhar R, Hayman T, Hoffe S E, et al. Body mass index and survival in esophageal adenocarcinoma treated with chemoradiotherapy followed by esophagectomy[J]. J Gastrointest Surg, 2012,16(7): 1296-1302.
Kelvin K, Chan W, Saluja R, et al. Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta-analysis [J]. Int J Cancer, 2018, 143(2): 430-437.
[5]
Van Hagen P, Hulshof M C, Van Lanschot J, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. N Engl J Med, 2012, 366(22): 2074-2084.
[6]
Almhanna K, Shridhar R, Meredith K L. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: is there a standard of care? [J]. Cancer Control, 2013, 20(2): 89-96.
[7]
Ychou M, Boige V, Pignon J P, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase Ⅲ trial [J]. J Clin Oncol, 2011, 29 (13): 1715-1721.
[8]
Cunningham D, Allum W H, Stenning S P, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. N Engl J Med, 2006, 355(1):11-20.
[9]
Tam V, Hooker C M, Molena D, et al. Clinical response to neoadjuvant therapy to predict success of adjuvant chemotherapy for esophageal adenocarcinoma[J]. J Clin Oncol, 2014,32: 137.
[10]
Saeed N A, Mellon E A, Meredith K L,et al. Adjuvant chemotherapy and outcomes in esophageal carcinoma[J]. J Gastroint Oncol, 2017, 8(5): 816-824.
Guo Xufeng, Mao Teng, Gu Zhitao, et al. Clinical study on postoperative recurrence in patients with pN1 esophageal squamous cell carcinoma[J]. Thoracic Cancer, 2015, 6(2):146-150.
[13]
Pasquer A, Gronnier C, Renaud F, et al. Impact of adjuvant chemotherapy on patients with lymph node-positive esophageal cancer who are primarily treated with surgery [J]. Ann Surg Oncol, 2015, 22 (Suppl 3): S1340-1349.
2018, Vol. 29 
